National Institutes of Health: Breast Neoplasms trials

The registry lists 285 Breast Neoplasms studies with National Institutes of Health as lead sponsor. 21 are open to participants now and 80 have results posted.

Early Phase 1 3Phase 1 99Phase 2 115Phase 3 20No phase 69(a study in two phases counts in both)

Studies

Page 3 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast CancerCompletedNCT00079625Phase 1
• Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00079170Not applicable
• Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast CancerCompletedNCT00077363Phase 2
• Vaccine Therapy in Treating Patients With Metastatic Breast CancerTerminatedNCT00071942Phase 1
• Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2CompletedNCT00071383
• Use of Dynamic Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor-Associated Vasculature in Patients With Metastatic Breast CancerCompletedNCT00071357
• Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast CancerCompletedNCT00070252Phase 1/2
• Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast CancerCompletedNCT00070057Phase 1
• Acupuncture for Shortness of Breath in Cancer PatientsCompletedNCT00067691Not applicable
• Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT00064311Phase 1/2
• Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive CancerCompletedNCT00060372Phase 1
• Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast CancerCompletedNCT00055861Phase 2
• Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast CancerCompletedNCT00052728Phase 2
• Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast CancerCompletedNCT00052351Phase 2
• Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid TumorsTerminatedNCT00049608Phase 1
• Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast CancerCompletedNCT00049114Phase 2
• The Sister Study: Genetic and Environmental Risk Factors for Breast CancerCompletedNCT00047970
• Imatinib Mesylate in Treating Patients With Metastatic Breast CancerCompletedNCT00045188Phase 2
• Ixabepilone in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00045097Phase 2
• Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic RiskCompletedNCT00043472
• Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian CancerCompletedNCT00040222
• Massage Therapy for Cancer-Related FatigueCompletedNCT00039793Phase 2
• Trastuzumab and Flavopiridol in Treating Patients With Metastatic Breast CancerTerminatedNCT00039455Phase 1
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Decitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00030615Phase 1
• Erlotinib in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00030537Phase 2
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid TumorsCompletedNCT00028535Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• High-Risk Breast Duct EpitheliumCompletedNCT00028340
• Morbidity After Diagnosis and Treatment of Breast Cancer PatientsCompletedNCT00027118
• Morbidity Following the Diagnosis and Treatment of Patients With Breast CancerCompletedNCT00027105
• Study of Etoposide in Breast Cancer PatientsCompletedNCT00026949
• PS-341 in Treating Women With Metastatic Breast CancerCompletedNCT00025584Phase 2
• Trastuzumab and Gefitinib in Treating Patients With Metastatic Breast CancerCompletedNCT00024154Phase 2
• Radiolabeled Monoclonal Antibody Followed by Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Metastatic Breast CancerCompletedNCT00020410Phase 1
• Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast CancerCompletedNCT00020332Phase 1/2
• Vaccine Therapy in Treating Patients With Metastatic CancerCompletedNCT00020267Phase 1
• Allogeneic Peripheral Stem Cell Transplantation in Treating Patients With Stage IV Breast CancerCompletedNCT00020176Phase 2
• Complementary or Alternative Medicine Practices Used by Women at Increased Risk for Breast CancerCompletedNCT00020098Not applicable
• Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian CancerCompletedNCT00019916Phase 1/2
• Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2CompletedNCT00019812Phase 2
• Factors Affecting Weight Gain in Women Receiving Adjuvant Chemotherapy for Breast CancerTerminatedNCT00019643
• Raloxifene in Preventing Breast Cancer in Premenopausal WomenCompletedNCT00019500Phase 2
• LMB-9 Immunotoxin in Treating Patients With Advanced Solid TumorsCompletedNCT00019435Phase 1
• Vaccine Therapy and Biological Therapy in Treating Patients With Advanced CancerCompletedNCT00019084Phase 2
• Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory LymphomasCompletedNCT00019019Phase 1
• Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast CancerCompletedNCT00017394Phase 2
• Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast CancerCompletedNCT00016549Phase 2
• Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast CancerTerminatedNCT00016276Phase 3
• Phase I/II Trial of Doxil and Hyperthermia for Breast Cancer Patients With Chest Wall Recurrence or Stage IV Disease With Locally Advanced Breast CancerStatus unknownNCT00006433Phase 2
• Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle StudyCompletedNCT00006425
• Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up StudyCompletedNCT00006421
• Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast CancerCompletedNCT00006228Phase 2
• Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast CancerCompletedNCT00005970Phase 3
• Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast CancerCompletedNCT00005817Phase 2
• Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced CancerTerminatedNCT00005655Phase 1
• Prospective Study of Health in Runners and WalkersCompletedNCT00005494
• Susceptibility to Breast CancerCompletedNCT00004565
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• Gene Therapy Plus Chemotherapy in Treating Patients With Breast CancerCompletedNCT00004038Phase 1
• Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2CompletedNCT00003992Phase 2
• Irofulven in Treating Patients With Metastatic Breast CancerCompletedNCT00003796Phase 2
• Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or MetastaticCompletedNCT00003440Phase 3
• Microarray Analysis for Human Genetic DiseaseCompletedNCT00001898
• Effects of Raloxifene on the Uterus and Ovaries of Premenopausal PatientsCompletedNCT00001837
• Methods in Education for Breast Cancer GeneticsCompletedNCT00001806Phase 3
• A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by RituximabCompletedNCT00001805Phase 2
• Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast CancerCompletedNCT00001507Phase 1
• A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer PatientsCompletedNCT00001504Phase 1
• A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast CancerCompletedNCT00001498Phase 2
• Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast CancerCompletedNCT00001496
• Antimetabolite Induction, High-Dose Alkylating Agent Consolidation and Retroviral Transduction of the MDR1 Gene Into Peripheral Blood Progenitor Cells Followed by Intensification Therapy With Sequential Paclitaxel and Doxorubicin for Stage 4 Breast CancerCompletedNCT00001493Phase 2
• Outcomes of Education and Counseling for BRCA1 TestingCompletedNCT00001468
• Autologous T-Cell Transplantation and the Immunotherapy of Residual Disease in Breast Cancer: Pilot Study of Vaccine-Driven T-Cell Expansion in Patients Treated With Dose-Intensive ChemotherapyCompletedNCT00001440Phase 1
• Positron Emission Tomography in Patients With Breast CancerCompletedNCT00001385
• A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer PatientsCompletedNCT00001384Phase 2
• A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast CancerCompletedNCT00001378Phase 1
• A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast CancerCompletedNCT00001338Phase 3
• Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and LymphomaCompletedNCT00001270Phase 1
• Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast CancerCompletedNCT00001269Phase 1
• Effect of Preoperative Chemotherapy on Axillary Lymph Node Metastases in Stage II Breast Cancer: A Prospective Randomized TrialCompletedNCT00001250Phase 2
• Combination Chemotherapy (FLAC) Combined With Granulocyte-Macrophage Colony Stimulating Factor in Locally Advanced and Metastatic Breast CancerCompletedNCT00001239Phase 2
• A Multimodality Treatment Approach to Patients With Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast CancerCompletedNCT00001193Phase 2
• Women's Health Initiative (WHI)CompletedNCT00000611Phase 3